Bali Muralidhar

Managing Partner and Chief Investment Officer, Abingworth

Bali has 15 years of professional experience in healthcare across a range of functions including venture investing, R&D, clinical practice, and teaching. He works with the team in the London, Boston, and Menlo Park offices to source and evaluate new investment opportunities and support existing venture investments through to exit. He represents Abingworth on the boards of Anjarium, Exicure Inc., NuCana, Reneo, Spruce Biosciences, and Wugen. He led Abingworth’s investment in Glycomine and is an observer on the board. Bali is an executive officer on the joint steering committee of CymaBay and since 2021 Bali has been a member of the BVCA Venture Capital Committee.

Prior to joining Abingworth, Bali was a senior partner at MVM Partners LLP in London where he completed investments in and served on the boards of several companies, both public and private. Two of these were Wilson Therapeutics and Valneva, both also Abingworth portfolio companies. In 2018, Bali was named among Financial News’ Rising Stars in Private Equity, which celebrated 25 men and women under the age of 40 standing out in the European private equity industry. Before MVM, Bali was a member of Bain Capital’s healthcare deal team.
Bali obtained a degree in clinical medicine from the University of Oxford and practiced general surgery at the John Radcliffe and Addenbrooke’s Hospitals in Oxford and Cambridge, respectively. He has a PhD in translational cancer research from the MRC Cancer Cell Unit, University of Cambridge, and has published over a dozen peer reviewed papers. He was also a Bye-Fellow in Medical Sciences at Downing College, Cambridge where he taught pathology, surgery, and medicine.